A Case Report of a Well-Differentiated Neuroendocrine Tumor in which Sunitinib Treatment Resulted an Effective Response of Disease

#2157

Introduction: A case report of no pancreatic well-differentiated neuroendocrine tumor in which sunitinib treatment resulted an effective response of disease

Aim(s): A 24 year old man had a primary carcinoid tumor (NET 2) with multiple liver metastasis and ileal tumor, Since no drug were approved for NETS at that time in Algeria,

Materials and methods: We treated him after surgery of the primary and sandostatine LAR with sunitinib after approval by my head of my department of oncology and informed consent of the patient , Sunitinib was administered at daily dose of 37,5 mg/day with good tolerability since 2010 ,The non-hematological toxicity was hand and foot syndrome (G2) and controlled with topics and fatigue (G2 ) , CT revealed stable disease after 3 months of treatment for 36 months with safety profile than PR of liver metastasis with therapeutic windows sometimes . we preconize surgery in 6 of June 2014 and we obtain very good response and no liver lesion in the CT of April 2015 than we decided to maintain the patient under 25 mg of sunitinib because he had asthenia (G2 and sometimes G3)

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: SAI R,

Keywords: WD NET, SUNITINIB, NO pNET, Efficacy and safety,